15 results on '"Gossage, James"'
Search Results
2. Comparing Characteristics and Treatment of Brain Vascular Malformations in Children and Adults with HHT
- Author
-
Kilian, Alexandra, Latino, Giuseppe A, White, Andrew J, Ratjen, Felix, McDonald, Jamie, Whitehead, Kevin J, Gossage, James R, Krings, Timo, Lawton, Michael T, Kim, Helen, Faughnan, Marie E, and Group, The Brain Vascular Malformation Consortium HHT Investigator
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Pediatric Research Initiative ,Hematology ,Congenital Structural Anomalies ,Rare Diseases ,Orphan Drug ,Prevention ,Pediatric ,Clinical Research ,Brain Disorders ,Neurosciences ,hereditary hemorrhagic telangiectasia ,pediatrics ,brain vascular malformation ,embolization ,gamma knife ,surgery ,intracranial hemorrhage ,screening ,Biomedical and clinical sciences - Abstract
Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant disease characterized by the development of vascular malformations (VMs) in organs such as the brain and lungs, as well as telangiectases on mucosal surfaces. Prophylactic treatment of organ VMs may prevent potential complications, such as hemorrhage. However, brain VM treatment-surgical resection, embolization, and/or radiosurgery-is not recommended for all patients due to the associated risks. Given the scarcity of data regarding HHT-related brain VM presentation and treatment trends in pediatric patients, we aim to describe the clinical presentations and the patterns of treatment of HHT-related brain VMs in a pediatric cohort, and compare pediatric trends to those of adults. Demographic and clinical data were analyzed in 114 pediatric patients with HHT-related brain VMs and compared with a cohort of 253 adult patients enrolled in the multicenter Brain Vascular Malformation Consortium HHT Project. Our data demonstrated that a higher proportion of pediatric patients with HHT-related brain VMs were symptomatic at presentation (p = 0.004). Moreover, a higher proportion of pediatric patients presented with intracranial hemorrhage (p < 0.001) and seizure (p = 0.002) compared to adult patients. Surgical resection was the most common brain VM treatment modality in both children and adults. We conclude that pediatric patients may be more likely to present with symptoms and complications from brain VMs, supporting the case for screening for brain VMs in children with HHT.
- Published
- 2023
3. Genotype-Phenotype Correlations in Children with HHT.
- Author
-
Kilian, Alexandra, Latino, Giuseppe A, White, Andrew J, Clark, Dewi, Chakinala, Murali M, Ratjen, Felix, McDonald, Jamie, Whitehead, Kevin, Gossage, James R, Lin, Doris, Henderson, Katharine, Pollak, Jeffrey, McWilliams, Justin P, Kim, Helen, Lawton, Michael T, Faughnan, Marie E, and the Brain Vascular Malformation Consortium HHT Investigator Group
- Subjects
the Brain Vascular Malformation Consortium HHT Investigator Group ,ACVRL1 ,ENG ,Hereditary hemorrhagic telangiectasia ,SMAD4 ,arteriovenous malformation ,genotype–phenotype correlation ,pediatrics ,genotype-phenotype correlation ,Clinical Sciences - Abstract
Hereditary hemorrhagic telangiectasia (HHT), a rare autosomal dominant disease mostly caused by mutations in three known genes (ENG, ACVRL1, and SMAD4), is characterized by the development of vascular malformations (VMs). Patients with HHT may present with mucocutaneous telangiectasia, as well as organ arteriovenous malformations (AVMs) of the central nervous system, lungs, and liver. Genotype-phenotype correlations have been well described in adults with HHT. We aimed to investigate genotype-phenotype correlations among pediatric HHT patients. Demographic, clinical, and genetic data were collected and analyzed in 205 children enrolled in the multicenter Brain Vascular Malformation Consortium HHT Project. A chi-square test was used to determine the association between phenotypic presentations and genotype. Among 205 patients (age range: 0-18 years; mean: 11 years), ENG mutation was associated with the presence of pulmonary AVMs (p < 0.001) and brain VM (p < 0.001). The presence of a combined phenotype-defined as both pulmonary AVMs and brain VMs-was also associated with ENG mutation. Gastrointestinal bleeding was rare (4.4%), but was associated with SMAD4 genotype (p < 0.001). We conclude that genotype-phenotype correlations among pediatric HHT patients are similar to those described among adults. Specifically, pediatric patients with ENG mutation have a greater prevalence of pulmonary AVMs, brain VMs, and a combined phenotype.
- Published
- 2020
4. Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia
- Author
-
Parambil, Joseph G., Gossage, James R., McCrae, Keith R., Woodard, Troy D., Menon, K. V. Narayanan, Timmerman, Kasi L., Pederson, Douglas P., Sprecher, Dennis L., and Al-Samkari, Hanny
- Published
- 2022
- Full Text
- View/download PDF
5. Brain arteriovenous malformations associated with hereditary hemorrhagic telangiectasia: Gene–phenotype correlations
- Author
-
Nishida, Takeo, Faughnan, Marie E, Krings, Timo, Chakinala, Murali, Gossage, James R, Young, William L, Kim, Helen, Pourmohamad, Tony, Henderson, Katharine J, Schrum, Stacy D, James, Melissa, Quinnine, Nancy, Bharatha, Aditya, terBrugge, Karel G, and White, Robert I
- Subjects
Biological Sciences ,Biomedical and Clinical Sciences ,Genetics ,Congenital Structural Anomalies ,Hematology ,Pediatric ,Brain Disorders ,Neurosciences ,Stroke ,Clinical Research ,Rare Diseases ,Activin Receptors ,Type II ,Adolescent ,Adult ,Aged ,Antigens ,CD ,Arteriovenous Fistula ,Child ,Child ,Preschool ,Endoglin ,Female ,Genetic Association Studies ,Humans ,Infant ,Infant ,Newborn ,Intracellular Signaling Peptides and Proteins ,Intracranial Arteriovenous Malformations ,Male ,Middle Aged ,Mutation ,Receptors ,Cell Surface ,Smad4 Protein ,Telangiectasia ,Hereditary Hemorrhagic ,Young Adult ,hereditary hemorrhagic telangiectasia ,brain arteriovenous malformation ,genotype ,intracranial hemorrhage ,Clinical Sciences ,Clinical sciences - Abstract
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant genetic disease with a wide spectrum of vascular malformations (VMs) involving multiple organs. Nine to 16% of patients with HHT harbor brain arteriovenous malformations (AVMs), which can cause intracranial hemorrhage (ICH). Our objective was to study clinical manifestations of brain AVMs in patients with HHT and correlate these with the specific gene mutated. We reviewed records of 171 patients with HHT and brain AVMs. A history of ICH was found in 27% (41/152) patients, with a mean age of 26 ± 18 range, (0-68) years. All of patients with ICH were neurologically asymptomatic prior to ICH. Multiple brain AVMs were found in 23% (170/39) of patients on initial examination. Genetic test results were available in 109 (64%) patients. Mutations in ENG, ACVRL1, and SMAD4 were present in 75 (69%), 18 (17%), and 2 (2%), respectively. A history of ICH was reported in 24% of patients with an ENG mutation and 27% of patients with an ACVRL1 mutation, with a mean age of 26 ± 16 (range, 2-50) and 18 ± 21 (0-48) years, respectively. No statistically significant differences in age at first brain AVM diagnosis, prevalence of ICH history, age at ICH, or other manifestations of brain AVMs were observed among gene groups. In conclusion, no evidence for differences in brain AVM characteristics was observed among HHT gene groups, although we cannot exclude clinically important differences. Larger studies are needed to further guide brain AVM screening decisions in patients with HHT.
- Published
- 2012
6. Long Term Survival of Heritable Pulmonary Arterial Hypertension Associated with Hereditary Hemorrhagic Telangiectasia: A Case Series.
- Author
-
Jamindar, Parth, Pope, Michael, and Gossage, James
- Subjects
HEREDITARY hemorrhagic telangiectasia ,PULMONARY arterial hypertension ,GENETIC disorders ,ARTERIOVENOUS malformation ,PULMONARY hypertension ,TELANGIECTASIA - Abstract
Hereditary hemorrhagic telangiectasia (HHT) is a hereditary disease characterized by recurrent epistaxis, mucocutaneous telangiectasias, and visceral arteriovenous malformations. Multiple genetic mutations have been linked to this rare disease, including ENG, ALK1 (ACVRL1), and MADH4. Pulmonary hypertension is a potential complication of HHT, with the most common phenotypes being World Health Organization (WHO) group 1 heritable pulmonary arterial hypertension (PAH), which is typically associated with ALK1 mutation; WHO group 2 pulmonary hypertension due to high output heart failure from hepatic arteriovenous malformations and/or anemia; and WHO group 2 due to high pulmonary artery wedge pressure. There is scarce evidence to help guide treatment of heritable PAH in HHT, and observational literature suggests that patients with HHT and heritable PAH have a worse prognosis compared to patients with idiopathic PAH. We describe the diagnosis, pulmonary hemodynamics, and detailed treatment courses of three patients with ALK1-associated HHT and PAH, who all exhibited objective clinical improvement with parenteral prostacyclins and oral agents. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Executive summary of the 11th HHT international scientific conference
- Author
-
Arthur, Helen, Geisthoff, Urban, Gossage, James R., Hughes, Christopher C. W., Lacombe, Pascal, Meek, Mary E., Oh, Paul, Roman, Beth L., Trerotola, Scott O., Velthuis, Sebastiaan, and Wooderchak-Donahue, Whitney
- Published
- 2015
- Full Text
- View/download PDF
8. Quantification metrics for telangiectasia using optical coherence tomography.
- Author
-
Cardinell, Jillian L., Ramjist, Joel M., Chen, Chaoliang, Shi, Weisong, Nguyen, Nhu Q., Yeretsian, Tiffany, Choi, Matthew, Chen, David, Clark, Dewi S., Curtis, Anne, Kim, Helen, Faughnan, Marie E., Yang, Victor X. D., the Brain Vascular Malformation Consortium HHT Investigator Group, Chakinala, Murali, Clancy, Marianne S., Faughnan, Marie, Gossage, James R., Henderson, Katharine, and Iyer, Vivek
- Subjects
HEREDITARY hemorrhagic telangiectasia ,TELANGIECTASIA ,BLOOD flow - Abstract
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder that causes vascular malformations throughout the body. The most prevalent and accessible of these lesions are found throughout the skin and mucosa, and often rupture causing bleeding and anemia. A recent increase in potential HHT treatments have created a demand for quantitative metrics that can objectively measure the efficacy of new and developing treatments. We employ optical coherence tomography (OCT)—a high resolution, non-invasive imaging modality in a novel pipeline to image and quantitatively characterize dermal HHT lesion behavior over time or throughout the course of treatment. This study is aimed at detecting detailed morphological changes of dermal HHT lesions to understand the underlying dynamic processes of the disease. We present refined metrics tailored for HHT, developed from a pilot study using 3 HHT patients and 6 lesions over the course of multiple imaging dates, totalling to 26 lesion images. Preliminary results from these lesions are presented in this paper alongside representative OCT images. This study provides a new objective method to analyse and understand HHT lesions using a minimally invasive, accessible, cost-effective, and efficient imaging modality with quantitative metrics describing morphology and blood flow. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Utility of modified Rankin Scale for brain vascular malformations in hereditary hemorrhagic telangiectasia.
- Author
-
Thompson, K. P., Nelson, J., Kim, H., Weinsheimer, S. M., Marchuk, D. A., Lawton, M. T., Krings, T., Faughnan, M. E., Brain Vascular Malformation Consortium HHT Investigator Group, Chakinala, Murali, Clancy, Marianne S., Faughnan, Marie E., Gossage, James R., Hetts, Steven W., Iyer, Vivek, Kasthuri, Raj S., Kim, Helen, Krings, Timo, Lawton, Michael T., and Lin, Doris
- Subjects
HEREDITARY hemorrhagic telangiectasia ,CEREBRAL arteriovenous malformations ,INTRACRANIAL hemorrhage ,TREATMENT effectiveness ,ARTERIOVENOUS malformation ,HUMAN abnormalities - Abstract
Background: Approximately 10% of hereditary hemorrhagic telangiectasia (HHT) patients harbour brain vascular malformations (VMs). Intracranial hemorrhage (ICH) from brain VMs can lead to death or morbidity, while treatment options for brain VMs also have associated morbidity. The modified Rankin Scale (mRS) may provide an approach to identifying HHT-brain VM patients with poor outcomes, and their predictors. We aimed to measure the relationship between mRS score and brain VM, brain VM number, as well as other aspects of HHT, at enrollment and during prospective follow-up.Methods: 1637 HHT patients (342 with brain VMs) were recruited from 14 HHT centres of the Brain Vascular Malformation Consortium since 2010 and followed prospectively (mean = 3.4 years). We tested whether the presence of brain VM, other HHT organ involvement, and HHT mutation genotype were associated with worse mRS scores at baseline and during follow-up, using linear mixed models, adjusting for age, sex, and year of visit.Results: Presence of brain VMs was not associated with worse mRS score at baseline and there was no significant worsening of mRS with prospective follow-up in these patients; 92% had baseline mRS of 0-2. HHT-related gastrointestinal (GI) bleeding was associated with worse mRS scores at baseline (0.37, 95% CI 0.26-0.47, p < 0.001), as were history of anemia (0.35, 95% CI 0.27-0.43, p < 0.001) and liver VMs (0.19, 95% CI 0.09-0.30, p < 0.001). Presence of pulmonary arteriovenous malformations (AVMs) was not associated with worse mRS scores at baseline. mRS score was not associated with either HHT genotype (Endoglin vs ACVRL1). Only GI bleeding was associated with a significantly worsening mRS during prospective follow-up (0.64, 95% CI 0.21-1.08, p = 0.004).Conclusion: Most HHT-brain VM patients had good functional capacity (mRS scores 0-2) at baseline that did not change significantly over 3.4 mean years of follow-up, suggesting that mRS may not be useful for predicting or measuring outcomes in these patients. However, HHT patients with GI bleeding, anemia history or liver VMs had worse mRS scores, suggesting significant impact of these manifestations on functional capacity. Our study demonstrates the insensitivity of the mRS as an outcomes measure in HHT brain VM patients and reinforces the continued need to develop outcomes measures, and their predictors, in this group. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
10. Predictors of mortality in patients with hereditary hemorrhagic telangiectasia.
- Author
-
Thompson, K. P., Nelson, J., Kim, H., Pawlikowska, L., Marchuk, D. A., Lawton, M. T., Faughnan, Marie E., the Brain Vascular Malformation Consortium HHT Investigator Group, Chakinala, Murali, Clancy, Marianne S., Gossage, James R., Henderson, Katharine, Iyer, Vivek, Kasthuri, Raj S., Kim, Helen, Krings, Timo, Lawton, Michael T., Lin, Doris, Mager, Hans-Jurgen, and Marchuk, Douglas A.
- Subjects
HEREDITARY hemorrhagic telangiectasia ,DEATH forecasting ,MORTALITY ,ARTERIOVENOUS malformation ,GASTROINTESTINAL hemorrhage ,RESEARCH ,RESEARCH methodology ,RETROSPECTIVE studies ,CELL receptors ,MEDICAL cooperation ,EVALUATION research ,ARTERIOVENOUS fistula ,COMPARATIVE studies ,RESEARCH funding ,LONGITUDINAL method - Abstract
Background: Retrospective questionnaire and healthcare administrative data suggest reduced life expectancy in untreated hereditary hemorrhagic telangiectasia (HHT). Prospective data suggests similar mortality, to the general population, in Denmark's centre-treated HHT patients. However, clinical phenotypes vary widely in HHT, likely affecting mortality. We aimed to measure predictors of mortality among centre-treated HHT patients. HHT patients were recruited at 14 HHT centres of the Brain Vascular Malformation Consortium (BVMC) since 2010 and followed annually. Vital status, organ vascular malformations (VMs) and clinical symptoms data were collected at baseline and during follow-up (N = 1286). We tested whether organ VMs, HHT symptoms and HHT genes were associated with increased mortality using Cox regression analysis, adjusting for patient age, sex, and smoking status.Results: 59 deaths occurred over average follow-up time of 3.4 years (max 8.6 years). A history of anemia was associated with increased mortality (HR = 2.93, 95% CI 1.37-6.26, p = 0.006), as were gastro-intestinal (GI) bleeding (HR = 2.63, 95% CI 1.46-4.74, p = 0.001), and symptomatic liver VMs (HR = 2.10, 95% CI 1.15-3.84, p = 0.015). Brain VMs and pulmonary arteriovenous malformations (AVMs) were not associated with mortality (p > 0.05). Patients with SMAD4 mutation had significantly higher mortality (HR = 18.36, 95% CI 5.60-60.20, p < 0.001) compared to patients with ACVRL1 or ENG mutation, but this estimate is imprecise given the rarity of SMAD4 patients (n = 33, 4 deaths).Conclusions: Chronic GI bleeding, anemia and symptomatic liver VMs are associated with increased mortality in HHT patients, independent of age, and in keeping with the limited treatment options for these aspects of HHT. Conversely, mortality does not appear to be associated with pulmonary AVMs or brain VMs, for which patients are routinely screened and treated preventatively at HHT Centres. This demonstrates the need for development of new therapies to treat chronic anemia, GI bleeding, and symptomatic liver VMs in order to reduce mortality among HHT patients. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
11. Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia.
- Author
-
Faughnan, Marie E., Gossage, James R., Chakinala, Murali M., Oh, S. Paul, Kasthuri, Raj, Hughes, Christopher C. W., McWilliams, Justin P., Parambil, Joseph G., Vozoris, Nicholas, Donaldson, Jill, Paul, Gitanjali, Berry, Pamela, and Sprecher, Dennis L.
- Subjects
HEREDITARY hemorrhagic telangiectasia ,NOSEBLEED ,TELANGIECTASIA ,VASCULAR endothelial growth factor receptors ,KINASE inhibitors - Abstract
Pazopanib (Votrient) is an orally administered tyrosine kinase inhibitor that blocks VEGF receptors potentially serving as anti-angiogenic treatment for hereditary hemorrhagic telangiectasia (HHT). We report a prospective, multi-center, open-label, dose-escalating study [50 mg, 100 mg, 200 mg, and 400 mg], designed as a proof-of-concept study to demonstrate efficacy of pazopanib on HHT-related bleeding, and to measure safety. Patients, recruited at 5 HHT Centers, required ≥ 2 Curacao criteria AND [anemia OR severe epistaxis with iron deficiency]. Co-primary outcomes, hemoglobin (Hgb) and epistaxis severity, were measured during and after treatment, and compared to baseline. Safety monitoring occurred every 1.5 weeks. Seven patients were treated with 50 mg pazopanib daily. Six/seven showed at least 50% decrease in epistaxis duration relative to baseline at some point during study; 3 showed at least 50% decrease in duration during Weeks 11 and 12. Six patients showed a decrease in ESS of > 0.71 (MID) relative to baseline at some point during study; 3/6 showed a sustained improvement. Four patients showed > 2 gm improvement in Hgb relative to baseline at one or more points during study. Health-related QOL scores improved on all SF-36 domains at Week 6 and/or Week 12, except general health (unchanged). There were 19 adverse events (AE) including one severe AE (elevated LFTs, withdrawn from dosing at 43 days); with no serious AE. In conclusion, we observed an improvement in Hgb and/or epistaxis in all treated patients. This occurred at a dose much lower than typically used for oncologic indications, with no serious AE. Further studies of pazopanib efficacy are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
12. Screening for pulmonary and brain vascular malformations is the North American standard of care for patients with hereditary hemorrhagic telangiectasia (HHT): A survey of HHT Centers of Excellence.
- Author
-
Kilian, Alexandra, Clancy, Marianne S, Olitsky, Scott, Gossage, James R, and Faughnan, Marie E
- Subjects
HEREDITARY hemorrhagic telangiectasia ,CEREBRAL arteriovenous malformations ,PATIENT care ,HUMAN abnormalities - Abstract
We designed a brief survey (see online supplemental material) to collect information about screening practices for pulmonary arteriovenous malformations (AVMs) and brain VMs in adult and pediatric (age < 18) patients with HHT. In addition, we report that 82% of North American HHT Centers are routinely recommending pulmonary AVM screening for children, in keeping with international guidelines.[4] The centers not routinely recommending screening for pulmonary AVMs in children reported that they were not routinely caring for pediatric patients. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
13. Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial.
- Author
-
Whitehead, Kevin J., Sautter, Nathan B., McWilliams, Justin P., Chakinala, Murali M., Merlo, Christian A., Johnson, Maribeth H., James, Melissa, Everett, Eric M., Clancy, Marianne S., Faughnan, Marie E., Oh, S. Paul, Olitsky, Scott E., Pyeritz, Reed E., and Gossage, James R.
- Subjects
INTRANASAL medication ,ANTIFIBRINOLYTIC agents ,BLOOD transfusion ,COMPARATIVE studies ,RESEARCH methodology ,MEDICAL cooperation ,NEOVASCULARIZATION inhibitors ,NOSEBLEED ,QUALITY of life ,RESEARCH ,CUTANEOUS therapeutics ,EVALUATION research ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,BLIND experiment ,SEVERITY of illness index ,HEREDITARY hemorrhagic telangiectasia ,TRANEXAMIC acid ,DISEASE complications - Abstract
Importance: Epistaxis is a major factor negatively affecting quality of life in patients with hereditary hemorrhagic telangiectasia (HHT; also known as Osler-Weber-Rendu disease). Optimal treatment for HHT-related epistaxis is uncertain.Objective: To determine whether topical therapy with any of 3 drugs with differing mechanisms of action is effective in reducing HHT-related epistaxis.Design, Setting, and Participants: The North American Study of Epistaxis in HHT was a double-blind, placebo-controlled randomized clinical trial performed at 6 HHT centers of excellence. From August 2011 through March 2014, there were 121 adult patients who met the clinical criteria for HHT and had experienced HHT-related epistaxis with an Epistaxis Severity Score of at least 3.0. Follow-up was completed in September 2014.Interventions: Patients received twice-daily nose sprays for 12 weeks with either bevacizumab 1% (4 mg/d), estriol 0.1% (0.4 mg/d), tranexamic acid 10% (40 mg/d), or placebo (0.9% saline).Main Outcomes and Measures: The primary outcome was median weekly epistaxis frequency during weeks 5 through 12. Secondary outcomes included median duration of epistaxis during weeks 5 through 12, Epistaxis Severity Score, level of hemoglobin, level of ferritin, need for transfusion, emergency department visits, and treatment failure.Results: Among the 121 patients who were randomized (mean age, 52.8 years [SD, 12.9 years]; 44% women with a median of 7.0 weekly episodes of epistaxis [interquartile range {IQR}, 3.0-14.0]), 106 patients completed the study duration for the primary outcome measure (43 were women [41%]). Drug therapy did not significantly reduce epistaxis frequency (P = .97). After 12 weeks of treatment, the median weekly number of bleeding episodes was 7.0 (IQR, 4.5-10.5) for patients in the bevacizumab group, 8.0 (IQR, 4.0-12.0) for the estriol group, 7.5 (IQR, 3.0-11.0) for the tranexamic acid group, and 8.0 (IQR, 3.0-14.0) for the placebo group. No drug treatment was significantly different from placebo for epistaxis duration. All groups had a significant improvement in Epistaxis Severity Score at weeks 12 and 24. There were no significant differences between groups for hemoglobin level, ferritin level, treatment failure, need for transfusion, or emergency department visits.Conclusions and Relevance: Among patients with HHT, there were no significant between-group differences in the use of topical intranasal treatment with bevacizumab vs estriol vs tranexamic acid vs placebo and epistaxis frequency.Trial Registration: clinicaltrials.gov Identifier: NCT01408030. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
14. Somatic mutations in arteriovenous malformations in hereditary hemorrhagic telangiectasia support a bi-allelic two-hit mutation mechanism of pathogenesis.
- Author
-
DeBose-Scarlett, Evon, Ressler, Andrew K., Gallione, Carol J., Sapisochin Cantis, Gonzalo, Friday, Cassi, Weinsheimer, Shantel, Schimmel, Katharina, Spiekerkoetter, Edda, Kim, Helen, Gossage, James R., Faughnan, Marie E., and Marchuk, Douglas A.
- Subjects
- *
SOMATIC mutation , *HEREDITARY hemorrhagic telangiectasia , *ARTERIOVENOUS malformation , *PHENOTYPES , *CHROMOSOMES , *CEREBRAL arteriovenous malformations - Abstract
Hereditary hemorrhagic telangiectasia (HHT) is an inherited disorder of vascular malformations characterized by mucocutaneous telangiectases and arteriovenous malformations (AVMs) in internal organs. HHT is caused by inheritance of a loss of function mutation in one of three genes. Although individuals with HHT are haploinsufficient for one of these genes throughout their entire body, rather than exhibiting a systemic vascular phenotype, vascular malformations occur as focal lesions in discrete anatomic locations. The inconsistency between genotype and phenotype has provoked debate over whether haploinsufficiency or a different mechanism gives rise to the vascular malformations. We previously showed that HHT-associated skin telangiectases develop by a two-hit mutation mechanism in an HHT gene. However, somatic mutations were identified in only half of the telangiectases, raising the question whether a second-hit somatic mutation is a necessary (required) event in HHT pathogenesis. Here, we show that another mechanism for the second hit is loss of heterozygosity across the chromosome bearing the germline mutation. Secondly, we investigate the two-hit mutation mechanism for internal organ AVMs, the source of much of the morbidity of HHT. Here, we identified somatic molecular genetic events in eight liver telangiectases, including point mutations and a loss of heterozygosity event. We also identified somatic mutations in one pulmonary AVM and two brain AVMs, confirming that mucocutaneous and internal organ vascular malformations undergo the same molecular mechanisms. Together, these data argue that bi-allelic loss of function in an HHT gene is a required event in the pathogenesis of HHT-associated vascular malformations. Hereditary hemorrhagic telangiectasia is an autosomal-dominant disorder consisting of focal vascular malformations. We show that some malformations acquire a somatic mutation in trans with the germline mutation, leading to bi-allelic gene loss. Others exhibit loss of heterozygosity across the chromosome bearing the germline mutation, supporting a two-hit mutation mechanism of pathogenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. De Novo Brain Vascular Malformations in Hereditary Hemorrhagic Telangiectasia.
- Author
-
Beslow, Lauren A., Krings, Timo, Kim, Helen, Hetts, Steven W., Lawton, Michael T., Ratjen, Felix, Whitehead, Kevin J., Gossage, James R., McCulloch, Charles E., Clancy, Marianne, Bagheri, Negar, and Faughnan, Marie E.
- Subjects
- *
HEREDITARY hemorrhagic telangiectasia , *CEREBRAL arteriovenous malformations , *HUMAN abnormalities , *SIZE of brain , *INTRACRANIAL hemorrhage - Abstract
Approximately 10% of people with hereditary hemorrhagic telangiectasia (HHT) have brain vascular malformations (VMs). Few reports describe de novo brain VM formation. International HHT Guidelines recommend initial brain VM screening upon HHT diagnosis in children but do not address rescreening. We aimed to confirm whether brain VMs can form de novo in patients with HHT. The Brain Vascular Malformation Consortium HHT project is a 17-center longitudinal study enrolling patients since 2010. We analyzed the database for de novo VMs defined as those detected (1) on follow-up neuroimaging in a patient without previous brain VMs or (2) in a location distinct from previously identified brain VMs and reported those in whom a de novo VM could be confirmed on central neuroimaging review. Of 1909 patients enrolled, 409 (21%) had brain VMs. Seven patients were recorded as having de novo brain VMs, and imaging was available for central review in four. We confirmed that three (0.7% of individuals with brain VMs) had de novo brain VMs (two capillary malformations, one brain arteriovenous malformation) with intervals of six, nine, and 13 years from initial imaging. Two with de novo brain VMs were <18 years. The fourth patient, a child, did not have a de novo brain VM but had a radiologically confirmed increase in size of an existing brain arteriovenous malformation. Brain VMs can, albeit rarely, form de novo in patients with HHT. Given the potential risk of hemorrhage from brain VMs, regular rescreening in patients with HHT may be warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.